ArticleChembiochem : a European journal of chemical biology2011
Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Article in Chembiochem : a European journal of chemical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Pooled it
- XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Active targeting towards bone cancer and metastases by pamidronate-bridged dinuclear platinum(II) complexes.Frontiers in chemistry · 2026Article
- Role of the nucleotide excision repair endonuclease XPF in the kinetoplastid parasite Trypanosoma brucei.Scientific reports · 2025Article
- Structure-specific nucleases in genome dynamics and strategies for targeting cancers.Journal of molecular cell biology · 2024Review
- Article
- Biological Evaluation of Dinuclear Platinum(II) Complexes with AromaticInternational journal of molecular sciences · 2024Review
- KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2.Molecular and cellular biochemistry · 2024Article
- Human NTHL1 expression and subcellular distribution determines cisplatin sensitivity in human lung epithelial and non-small cell lung cancer cells.NAR cancer · 2024Article
- Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.International journal of molecular sciences · 2022Review
- Nucleases as molecular targets for cancer diagnosis.Biomarker research · 2021Review
- DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.Molecular biology reports · 2021Review
- The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.Frontiers in pharmacology · 2020Review
- Periodic Oxaliplatin Administration in Synergy with PER2-MediatedAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- SLX4IP acts with SLX4 and XPF-ERCC1 to promote interstrand crosslink repair.Nucleic acids research · 2019Article
- Correlation of xeroderma pigmentosum complementation group F expression with gastric cancer and prognosis.Oncology letters · 2018Article
- Tdp1 processes chromate-induced single-strand DNA breaks that collapse replication forks.PLoS genetics · 2018Article
- Article
- Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage.British journal of pharmacology · 2017Article
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.Chemical reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Resistance of tumor cells to platinum anticancer agents poses a major problem in cancer chemotherapy. One of the mechanisms associated with platinum-based drug resistance is the enhanced capacity of the cell to carry out nucleotide excision repair (NER) on platinum-damaged DNA. Endonucleases XPF and XPG are critical components of NER, responsible for excising the damaged DNA strand to remove the DNA lesion. Here, we investigated possible consequences of down-regulation of XPF and XPG gene expression in osteosarcoma cancer cells (U2OS) and the impact on cellular transcription and DNA repair. We further evaluated the sensitivity of such cells toward the platinum anticancer drugs cisplatin and oxaliplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.